China’s rapid rise in drug development casts a long shadow over US oncology
2026 marks a clear turning point for China’s position in the global clinical trials arena, particularly in oncology. At this …
Post
-
-
Study deems it safe to switch children with pneumonia to oral antibiotics
Children hospitalised with severe pneumonia can safely switch from injectable to oral antibiotics once they begin to recover, a clinical …
-
Azafaros concludes Phase III trial recruitment for GM1/GM2 gangliosidoses
Netherlands-based biotechnology company Azafaros has completed patient recruitmentfor its Phase III study assessing nizubaglustat for GM1/GM2 gangliosidoses. A part of the …
-
J&J’s multiple myeloma combo cuts risk of death by 62% in Phase III study
Johnson & Johnson (J&J) has posted a duo of Phase III wins for two of its budding multiple myeloma combination …
-
Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013
Bio-Thera Solutions has initiated dosing in a Phase I clinical trial of BAT8013, an antibody drug conjugate (ADC) designed to …
-
Operation Trialblazer: Expedited IND delivers a strategic edge in dynamic global landscape
With Operation Trialblazer set to expedite early-stage research in the US, experts anticipate that the fast-tracked investigational new drug (IND) …
-
Another win for Lilly’s triple-g agonist in two more Phase III trials
Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded …
-
Arrowhead announces top line data from Phase III trials of plozasiran
Arrowhead Pharmaceuticals has reported top line results from the global Phase III SHASTA-3 and SHASTA-4 clinical trials investigating plozasiran in …
-
Ribo reports vortosiran Phase IIa trial results for coronary artery disease
Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals, collectively known as Ribo, has reported initial results from its Phase IIa …
-
Crystalys banks $130m to progress gout drug, plan for commercial readiness
Crystalys Therapeutics has secured $130m in a Series B raise to push its gout therapy, dotinurad, further down the pipeline, …
-
Summit debuts longer-term ivonescimab data as it awaits FDA NSCLC decision
Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits …
-
Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority
Gilead and MSD (Merck & Co) have released data for their two-drug combination human immunodeficiency virus (HIV) therapy, islatravir-lenacapavir (ISL/LEN), …
-
Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial
Celldex’s subcutaneous monoclonal antibody (mAb) has failed to show benefit in a Phase II prurigo nodularis (PN) trial.In the randomised, …
-
Innate Pharma concludes enrolment in dose escalation of IPH4502 study
French company Innate Pharma has completed patient enrolment in the dose escalation segment of the Phase I IPH4502-101 study, involving …
-
Devonian’s Phase II/III Thykamine paediatric study secures Health Canada approval
Devonian Health Group has received authorisation from Health Canada for its clinical trial application (CTA) to begin a Phase II/III study …
